Bank of New York Mellon Corp raised its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN – Free Report) by 71.6% in the third quarter, Holdings Channel.com reports. The firm owned 390,987 shares of the company’s stock after purchasing an additional 163,189 shares during the period. Bank of New York Mellon Corp’s holdings in OptiNose were worth $481,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. American International Group Inc. purchased a new position in shares of OptiNose during the 2nd quarter worth $43,000. Great Point Partners LLC grew its holdings in OptiNose by 12.0% during the 2nd quarter. Great Point Partners LLC now owns 8,839,939 shares of the company’s stock valued at $10,873,000 after purchasing an additional 945,203 shares during the last quarter. Velan Capital Investment Management LP boosted its position in OptiNose by 2.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 3,596,861 shares of the company’s stock valued at $4,424,000 after buying an additional 100,000 shares during the period. Virtu Financial LLC purchased a new stake in OptiNose in the 2nd quarter valued at about $41,000. Finally, Two Sigma Securities LLC purchased a new stake in OptiNose in the 1st quarter valued at about $55,000. Institutional investors own 57.21% of the company’s stock.
Insider Transactions at OptiNose
In other OptiNose news, CEO Ramy A. Mahmoud sold 52,875 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $1.31, for a total value of $69,266.25. Following the completion of the transaction, the chief executive officer now owns 548,387 shares of the company’s stock, valued at $718,386.97. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 68,994 shares of company stock valued at $87,803. Company insiders own 2.20% of the company’s stock.
OptiNose Stock Performance
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
- Five stocks we like better than OptiNose
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 attractive stocks that insiders are buying
- How to Invest in Lithium and Lithium Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Conference Calls and Individual Investors
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.